Prasugrel Shows Promise Over Ticagrelor for Diabetes Patients Post-PCI
A recent study challenges the status quo in post-PCI treatment for diabetes patients. The TUXEDO-2 trial reveals that ticagrelor might not be the preferred choice after all.
In the bustling city of New Orleans, a significant medical revelation emerged. The TUXEDO-2 trial, presented at the American Heart Association's 2025 Scientific Sessions, compared the effectiveness of ticagrelor and prasugrel in dual antiplatelet therapy (DAPT) for diabetes patients with multivessel coronary disease post-PCI.
The primary outcome, a composite of death, MI, stroke, or major bleeding, occurred in 16.57% of ticagrelor patients and 14.23% of prasugrel patients. This 2.33% difference, with a 95% confidence interval upper bound of 6.74%, crossed the 5% noninferiority margin, indicating a potential advantage for prasugrel.
But here's where it gets controversial... Nearly all outcome estimates pointed towards prasugrel's superiority, according to Dr. Sripal Bangalore, the study chair. This finding adds to the growing debate on the optimal DAPT regimen for diabetes patients post-PCI.
The ISAR-REACT 5 trial previously showed improved outcomes with prasugrel in ACS patients undergoing PCI. Now, TUXEDO-2 further supports the use of prasugrel over ticagrelor, especially in this specific patient population.
The TUXEDO-2 Trial in Focus
The ideal DAPT approach for diabetes patients post-PCI remains a puzzle, with limited data on ticagrelor and prasugrel. A prespecified analysis of ISAR-REACT 5 suggested similar outcomes for both drugs in diabetic patients, but TUXEDO-2 aimed to delve deeper.
Conducted across 66 Indian centers, TUXEDO-2 randomized 1,800 patients (average age 60, 72% men) to two different DES and DAPT regimens. The trial's design allowed for a comprehensive comparison of ticagrelor and prasugrel's safety and efficacy.
Most patients had type 2 diabetes, with a quarter requiring insulin. Prasugrel patients had slightly longer diabetes durations. The majority presented with MI, followed by chronic coronary syndrome and unstable angina.
Aspirin usage was consistent at discharge and during the 1-year follow-up. At discharge, ticagrelor and prasugrel usage differed slightly, but by 1 year, the proportions were nearly equal.
The higher primary composite outcome rate in ticagrelor patients was consistent across subgroups. Interestingly, ticagrelor seemed less effective in patients with shorter diabetes durations and high bleeding risk, though these findings were not statistically significant.
At 1 year, various outcomes showed no significant differences between ticagrelor and prasugrel, but prasugrel consistently had lower rates. This includes death, MI, stroke, major bleeding, nonfatal MI, and stent thrombosis.
Dr. Bangalore's presentation also included pooled results from TUXEDO-2 and ISAR-REACT 5, showing a significantly higher risk of death, MI, or stroke with ticagrelor and a nonsignificantly higher risk of major bleeding.
Prasugrel's Potential Rise
The question of which P2Y12 inhibitor is better has clinical significance, as Dr. Ajay Kirtane emphasized. With both drugs now available generically, cost is less of an issue, but side effects remain a consideration.
Ticagrelor is associated with dyspnea, which can lead to discontinuation, while prasugrel has a black box warning for patients over 75, with a history of stroke, or low body weight. These factors complicate the treatment decision.
Dr. Kirtane noted that while TUXEDO-2 has some limitations, it remains a well-powered randomized trial that fails to show ticagrelor's superiority. He suggested that prasugrel should be the preferred choice for ACS patients, especially in Indian populations, due to higher clopidogrel resistance rates.
The hope is that studies like TUXEDO-2 and ISAR-REACT 5 will encourage the use of prasugrel in appropriate ACS cases. Clinicians can adjust doses of P2Y12 inhibitors to manage bleeding risks, ensuring personalized and effective treatment.
For diabetes patients, the TUXEDO-2 results suggest prasugrel as a potentially better option. Dr. Jacqueline Tamis-Holland emphasized the need for aggressive preventive therapies in this high-risk group.
While TUXEDO-2 and ISAR-REACT 5 data support prasugrel's superiority, Dr. Tamis-Holland raised a thought-provoking question: Should these patients have undergone CABG instead of PCI? The 2021 revascularization guidelines recommend bypass surgery for this group to reduce mortality and repeat procedures, based on the FREEDOM trial.
TUXEDO-2 aims to compare its results with the CABG arm of FREEDOM, adding another layer of complexity to this medical debate. What do you think? Should prasugrel be the new standard for these patients, or is CABG the better approach? Share your insights in the comments!
